Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
113.00    1.50 (1.35%)
Bid:
112.00
Ask:
114.00
Spread: 2.00 (1.786%)
Market Cap: £67.98m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Year End Trading Update

17 Mar 2026 07:00

RNS Number : 8442W
Intercede Group PLC
17 March 2026
 

 

 

17 March 2026

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

Year End Trading Update

Intercede, the leading cybersecurity software company specialising in digital identities, today announces the following year end trading update for the financial year ending 31 March 2026 (FY26).

Performance Overview

Intercede expects to deliver continued Annual Recurring Revenue (ARR) growth in FY26, driven by increased support and maintenance revenues and further adoption of subscription-based licence income. This longer term strategic shift from perpetual licence sales to recurring revenue models will fundamentally enhance revenue quality, predictability, and long-term shareholder value.

 

Whilst the Group's ARR momentum is encouraging, full-year revenue is anticipated to be approximately 8-9% below current market expectations*. This reflects procurement delays, particularly in the United States, and customer purchasing deferrals attributable to heightened geopolitical uncertainty, including the ongoing Middle East conflict.

 

Critically, these opportunities are delayed, not lost. Active customer engagements continue across the pipeline, and order intake momentum improved in H2 FY26, validating underlying demand for the Group's solutions and products.

Financial Outlook FY26Revenue and Adjusted EBITDA

The revenue shortfall flows through to adjusted EBITDA, which is expected to be approximately 15-18% below current market expectations*. This reflects the impact of reduced revenues on a cost base that includes the continued strategic investment in growth initiatives designed to deliver long-term shareholder value.

 

Cash Generation and Balance Sheet Strength

 

Cash generation remains strong. Disciplined working capital management will result in positive operating cash flow, with cash balances at year-end expected approximately 3-5% ahead of current market expectations*. The Group maintains a debt-free balance sheet, providing financial flexibility, resilience, and the capacity to invest strategically.

 

Outlook - FY27 and Beyond

 

Intercede reaffirms its FY27 revenue target of £21 million, reflecting management's confidence that the FY26 revenue delays represent timing shifts rather than fundamental demand weakness.

 

This is based on:

· Pipeline strength: Active engagements continue with key customers and prospects;

· Improving order momentum: H2 FY26 upturn validates underlying demand for the Company's products and solutions; and

· Continued focus on a transition to a subscription model: Recurring revenue enhances customer retention and lifetime value.

The subscription transition is predicted to continue throughout FY27, with the board expecting delayed opportunities to convert into orders as geopolitical tensions stabilise, hopefully, and procurement cycles normalise. As conditions improve, the Group expects continued ARR growth to translate into improved revenue performance and visibility, supporting the medium-term growth trajectory.

Trading Update

The Group aims to report a more complete trading update with more detail on the FY26 unaudited revenue, constant currency analysis and actual cash and cash equivalents for the twelve months ended 31 March 2026 on 9 Apil 2026.

 

Klaas van der Leest, Chief Executive Officer at Intercede, commented:

 

"Whilst the FY26 revenue is disappointing, it has been impacted by procurement delays and customer caution arising from geopolitical uncertainty, and I want to emphasise three critical points for investors.

 

First, these are delays, not losses, as mentioned above. Our pipeline remains robust, customer engagements continue actively, and we are confident these opportunities will convert, especially should geopolitical conditions stabilise.

 

Second, our strategic transition to subscription-based solutions is accelerating. We are delivering continued ARR growth, fundamentally enhancing revenue quality, and building a more predictable, scalable business model that positions Intercede for sustained long-term success.

 

Finally , we reaffirm our FY27 revenue forecast of £21 million. This reflects our conviction that current headwinds represent timing effects, not structural challenges. Order intake momentum improved in H2, validating underlying demand.

 

We maintain a debt-free balance sheet, strong cash generation ahead of market expectations, and disciplined capital allocation. Intercede is well-positioned to deliver sustained ARR growth and long-term shareholder value."

 

\* The Board understands that current consensus market expectations for FY26 are consolidated revenues of £18.7m, adjusted EBITDA of £4.6m and cash and cash equivalents as at 31 March 2026 of £19.0m.

 

 

 

ENQUIRIES

Intercede Group plc

Tel. + 44 (0)1455 558111

Klaas van der Leest

CEO

Nitil Patel

CFO

 

 

Cavendish Capital Markets Limited

Tel. + 44 (0)20 7220 0500

Marc Milmo/Fergus Sullivan

Corporate Finance

Matt Lewis

ECM

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014) which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

About Intercede

Intercede is a cybersecurity software company specialising in digital identities, and its innovative solutions enable organisations to protect themselves against the number one cause of data breach: compromised user credentials.

 

The Intercede suite of products allows customers to choose the level of security that best fits their needs, from Secure Registration and ID Verification to Password Security Management, One-Time Passwords, FIDO and PKI. Uniquely, Intercede provides the entire set of authentication options from Passwords to PKI, supporting customers on their journey to passwordless and stronger authentication environments. In addition to developing and supporting Intercede software, the Group offers professional services and custom development capabilities as well as managing the world's largest password breach database.

 

For over 20 years, global customers in government, aerospace and defence, financial services, healthcare, telecommunications, cloud services and information technology have trusted Intercede solutions and expertise in protecting their mission critical data and systems at the highest level of assurance.

For more information visit: www.intercede.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKABKOBKDAND
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.